CTRI/2023/12/060478
Not yet recruiting
未知
Evaluation of efficacy, safety, and tolerance of a liposomal based cocktail of topical depigmenting agents for treatment of epidermal melasma - NI
SHNI Ventures LLP0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: L814- Other melanin hyperpigmentation
- Sponsor
- SHNI Ventures LLP
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Female and male patients, from 18\-45 years of age with epidermal melasma.
- •2\)Subjects with mild to moderate epidermal melasma.
- •3\)Participants who can provide a written informed consent and photo consent form.
- •4\)Participants who are willing to follow up for four visits over a period of 12 weeks.
- •5\)Participants who are able and willing to follow all the study procedures including abstinence from usage of any OTC product related to face applications.
- •6\)Participants who are willing to be clinically photographed as per protocol.
Exclusion Criteria
- •1\)Patient who is not willing to participate in the study.
- •2\)Patients who are using other pigment reduction creams (except sunscreen and a base moisturiser).
- •3\)Subjects with other dermatological disorder of the face that may interfere with the study evaluation (Acne, DPN, Seborrheic melanosis)
- •4\)Subjects with known hypersensitivity to any of the study compunds or constituents.
- •5\)Subjects who are expected to be exposed to the triggering factors (excessive sun exposure, UVB photo therapy, use of OCPs).
- •6\)Patient who has received facial procedures like dermabrasion, chemical peels, or laser procedures within the last 1 month.
- •7\)Any patient as per investigator’s opinion is unfit for participation in the study.
- •8\)Pregnant / lactating females.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCEEUCTR2005-006071-12-ITAZIENDA OSPEDALIERA SAN CAMILLO FORLANINI276
Completed
Phase 4
A clinical trial to study the effect of a Under eye Skin cream containing Biophytex LS 8740 and Proteasyl TP LS 8657 in patients with under eye dark circles.CTRI/2010/091/001346Glenmark Pharmaceutical limited500
Completed
Phase 4
A clinical trial to assess the efficacy, safety and tolerability of tigecycline in adult hospitalized patients with community acquired pneumonia (CAP).Health Condition 1: null- community acquired pneumonia (CAP)CTRI/2010/091/001439Glenmark Pharmaceuticals Limited120
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
Completed
Not Applicable
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd